What are the top VC firms for biotech and life sciences startups?

Biotech startups operate on a very different timeline than most software companies. For example, a SaaS startup might launch a product in months, quickly gather customer feedback, and iterate toward growth. But a biotech or life sciences company operates on a very different timeline and might spend years moving through research, validation, regulatory review, and clinical milestones before reaching going to market. That’s why working with an investment firm with sector specialization matters so much in biotech venture capital.

The best biotech and life sciences venture capital firms don’t just provide capital. They’ll help founders navigate scientific diligence, regulatory compliance, commercialization planning, and milestone-based fundraising over long development cycles. Also, biotech itself is no longer just one category. It spans therapeutics, synthetic biology, medical devices, healthcare infrastructure, research tooling, diagnostics, AI-enabled drug discovery, and much more. So, finding an investor who understands the nuances of your industry is essential.

This guide breaks down how founders can evaluate biotech VC firms and which investors stand out across different sectors and business stages.

Biotech fundraising operates on a different set of milestones. Instead of raising around revenue growth or user acquisition, founders often raise around scientific and regulatory progress, such as preclinical validation, regulatory filings, clinical trial data, manufacturing readiness, or commercial approvals.

The best biotech and life sciences venture capital firms often bring scientific and operational expertise alongside capital. Many have partners on staff with MDs or PhDs, or employ former operators of healthcare startups who can help evaluate research, recruit talent, and navigate commercialization.

Long-term capital matters, too. Biotech companies frequently require multiple rounds of financing over extended development timelines, particularly in therapeutics and medical devices. So, knowledgeable biotech VC firms tend to plan for that upfront and reserve capital for follow-on investments and supporting companies.

To learn more about how venture capital structures, ownership, and financing dynamics typically work, read Mercury’s venture capital primer and the guide to building a target investor list.

Not every biotech or life sciences venture capital firm will be the right fit for every company. For instance, a therapeutics-focused investor might have deep expertise in clinical trials but have little experience with healthcare infrastructure. Likewise, a healthcare software investor may know go-to-market strategy but struggle to evaluate the science. That’s why biotech founders should evaluate investors using the following three core questions.

1. Does this firm understand the science behind your product?

Scientific diligence matters far more in biotech than it does in other sectors. As mentioned earlier, the best biotech VC firms often have MDs, PhDs, clinicians, or experienced operators on staff, who can help founders evaluate regulation and compliance, clinical design, and hiring scientific talent.

2. Does this firm invest at the right stage and scale?

Early-stage firms are often more comfortable backing academic spinouts and preclinical companies. Later-stage investors tend to focus more heavily on companies that have met clinical milestones, demonstrate commercialization readiness, have a feasible manufacturing strategy, and are working towards expansion.

3. Is this a long-term partner?

Biotech development timelines can stretch on for years. That makes it important to evaluate potential investors and assess how they’ll likely react during challenging times, like delayed trials, regulatory setbacks, or difficult fundraising markets.

In the table below, we cover key areas to evaluate, as well as questions you can ask to get a sense of whether or not the firm could be a long-term fit.

For more tips on assessing potential VC firms read to work with, Mercury’s guide to finding a lead investor.

Here are a few biotech and life sciences VC firms worth paying attention to.

ARCH Venture Partners

ARCH Venture Partners is a biotech VC known for investing early and remaining deeply involved as companies scale over long commercialization cycles. Here’s some key info to know:

• Headquarters: Chicago, Illinois
• Stage focus: early-stage through growth-stage
• Sector specialization: therapeutics, genomics, frontier science platforms
• Notable portfolio companies: Illumina, Beam Therapeutics, Alnylam Pharmaceuticals, Juno Therapeutics, Receptos
• Typical investment profile: scientifically ambitious companies that are tackling technically difficult problems with large, long-term market potential
• Why founders consider this firm: The firm has a good reputation within deep biotech and it’s known for building scientific companies.
• Their approach: The firm tends to invest for the long-term in breakthrough science and platform technologies.

Flagship Pioneering

Flagship Pioneering is known for its unique approach to VC, preferring to build companies internally, more akin to an accelerator or foundry. Here’s some key info to know:

• Headquarters: Cambridge, Massachusetts
• Stage focus: company creation and early-stage investing
• Sector specialization: drug discovery and development, life sciences AI, disease prevention
• Notable portfolio companies: Moderna, Sana Biotechnology, Foghorn Therapeutics, Seres Therapeutics
• Typical investment profile: bioplatforms rooted in radical hypotheses
• Why founders consider this firm: The firm is known for its deep operational involvement and strong biotech ecosystem network.
• Their approach: The firm uses an internal venture creation model focused on building companies based on scientific breakthroughs.

OrbiMed

OrbiMed is one of the largest and most established healthcare-focused investment firms globally. It invests across nearly every segment of healthcare and life sciences. Here’s some key info to know:

• Headquarters: New York City, New York
• Stage focus: multi-stage, from early venture through public markets
• Sector specialization: therapeutics, medical devices, diagnostics, healthcare services
• Notable portfolio companies: Edgewise Therapeutics, Enliven Therapeutics, MDxHealth SA, BioAge Labs
• Typical investment profile: companies with strong scientific or healthcare market potential that are preparing for major growth or clinical or commercial milestones
• Why founders consider this firm: This firm has a deep healthcare network, large capital base, and experience supporting companies through long development and commercialization cycles.
• Their approach: They combine their wide-ranging areas of healthcare specialization with the ability to invest across both private and public markets.

RA Capital

RA Capital is widely respected for its scientific depth and long-term focus on life sciences investing. Here’s some key info to know:

• Headquarters: Boston, Massachusetts
• Stage focus: early-stage through clinical-stage growth investing
• Sector specialization: therapeutics, clinical development, drug discovery
• Notable portfolio companies: Aktis Oncology, Century Therapeutics, Secretome Therapeutics, Moderna
• Typical investment profile: biotech companies advancing through meaningful scientific, clinical, or regulatory milestones
• Why founders consider this firm: The firm is known for its rigorous scientific diligence capabilities and deep understanding of biotech commercialization pathways.
• Their approach: Their research-intensive investing is focused on long-term scientific and clinical value creation.

Third Rock Ventures

Third Rock Ventures is famous for its hands-on approach to company creation and involvement. Here’s some key info to know:

• Headquarters: Boston, Massachusetts
• Stage focus: seed through Series A, with later stage follow-on investment
• Sector specialization: therapeutics, medical devices and technology, health tech and diagnostics
• Notable portfolio companies: Azalea, Merida Biosciences, Inflection Medicine, Trace Neuroscience, Rapport Therapeutics
• Typical investment profile: early-stage biotech companies with founders with scientific expertise and commercial potential
• Why founders consider this firm: The firm gives hands-on support with leadership recruitment, clinical strategy, and company building.
• Their approach: They’re known for their intensive, early operational involvement with scientific founding teams.

In addition to these well-known biotech funds, some large generalist firms have also become important biotech players, such as Andreessen Horowitz and Google Ventures.

Early-stage biotech fundraising looks very different from raising a seed round for a software company. Because of that, early-stage biotech VC firms evaluate companies differently, and they often focus on:

• Scientific credibility
• Intellectual property and defensibility
• Regulatory feasibility
• Platform potential
• Strength of the founding and advisory team
• Early research or pharmaceutical partnerships

Investors are usually underwriting scientific progress and milestone potential, rather than near-term commercial traction.

Early-stage biotech investors also tend to play a more hands-on role operationally. Many help founders to recruit experienced leadership, shape regulatory strategy, connect with pharmaceutical partners, and prepare for clinical milestones and future fundraising rounds.

Universities, research hospitals, and incubators also play an outsized role in early biotech fundraising, and they might help VC firms identify promising science before companies fully commercialize. This also helps startups procure non-dilutive funding. Grants, government programs, and research partnerships are often significant in the fundraising strategy for biotech companies and can help meaningfully extend the runway.

To avoid missteps, read Mercury's guide to common fundraising mistakes.

As biotech startups scale, fundraising dynamics shift. Later-stage investors increasingly evaluate:

• Clinical outcomes
• Trial progression
• Regulatory milestones
• Commercial readiness
• Manufacturing strategy
• Reimbursement pathways
• Financial controls and reporting

Venture capital firms that invest in growth-stage life sciences startups often support later phases of clinical trial financing, commercial launch preparation, international expansion, strategic partnerships, IPO readiness, and more.

Late-stage biotech VC firms also tend to scrutinize operational maturity more heavily. By this stage, investors expect companies to demonstrate stronger financial infrastructure, forecasting discipline, and operational planning.

Biotech and life sciences venture capital is a broad category. Investors often specialize based on the type of science, regulatory pathway, commercialization model, or healthcare market they understand best. For founders, that specialization matters because different categories of investors will have different types of experience and knowledge.

Therapeutics-focused VC firms

Therapeutics-focused biotech VC firms often invest around scientific and clinical milestones, rather than commercial traction.

These investors typically spend significant time evaluating:

• Drug development timelines
• Clinical trial milestones
• Platform technologies
• Precision medicine
• Regulatory risk

Because therapeutics companies can require years of development before commercialization, investors in this category tend to have longer time horizons and larger reserve strategies. Firms like Third Rock Ventures and RA Capital Management are well known for this style of investing.

Medical device VC firms

Medical device investors operate with a different commercialization framework than therapeutics investors. In addition to regulatory approvals, these firms often focus heavily on:

• Regulatory pathways
• Hardware commercialization
• Hospital procurement cycles
• Manufacturing considerations
• Reimbursement dynamics

Medical device VC firms may also place greater emphasis on operations, execution, and commercialization readiness earlier in the company lifecycle. Large multi-stage healthcare investors, like OrbiMed, are active across many of these categories.

Life sciences tools and infrastructure investors

One of the fastest-growing areas in biotech venture capital is research infrastructure and scientific tooling. Areas of focus include:

• Research software
• Lab infrastructure
• Scientific automation
• Data platforms
• AI-enabled research tooling

Many of these businesses operate differently from traditional therapeutics companies and may scale more like enterprise software or infrastructure platforms. Firms, like ARCH Venture Partners, often invest in technically ambitious platform and infrastructure companies that are emerging from research environments.

Digital health and healthcare infrastructure investors

Healthcare infrastructure investors typically focus on the systems that support care delivery, operations, compliance, and healthcare workflows. That can include:

• Healthcare software
• Clinical workflow tools
• Compliance considerations
• Payer and provider ecosystems

Even software-heavy healthcare companies often face long procurement cycles, compliance requirements, and integration challenges.

Synthetic biology and deep biotech investors

Synthetic biology and deep biotech investors often back companies working on highly technical scientific platforms with long commercialization timelines. These investors might focus on companies in industrial biotech or bioengineering, for example:

• Industrial biotech
• Bioengineering
• Scientific defensibility
• Longer commercialization timelines
• Capital intensity

These firms are typically comfortable underwriting scientific risk over extended periods, especially when the underlying technology has strong platform potential. Flagship Pioneering is one of the best-known examples of a firm that’s operating heavily in this category.

The best founder-investor relationships usually come from alignment around scientific vision, commercialization strategy, and long-term timelines.

Financial operations become more complicated quickly in biotech companies, since this type of startup often manages milestone-based financing, research partnerships, international vendors, and operational complexity long before commercialization.

Mercury helps venture-backed startups manage banking, cards, payments, and financial workflows, all in one place, which can help biotech and life sciences founders manage burn more easily as their companies scale.

Ready to get started? Check out Mercury’s tools today.